1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Innovative Health Initiative Joint Undertaking (IHI JU) is a grant from the European Commission that funds collaborative, cross-sector health research projects spanning pharmaceutical, digital, IT, medical devices, and diagnostics industries.
The IHI JU aims to translate health research and innovation into tangible patient benefits by supporting breakthroughs that cross traditional sector boundaries, such as medical device-drug combinations and AI diagnostics. Projects span the full spectrum of care from prevention to diagnosis and treatment, with a focus on unmet public health needs and making Europe's health industries globally competitive.
Eligible applicants include health-related industries, SMEs, academic institutions, clinical organizations, patient organizations, and other health research entities from EU member states. Award amounts vary by project call.
Get alerted about grants like this
Save a search for “European Commission” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Innovative Health Initiative JU – IHI JU | European Union Innovative Health Initiative Joint Undertaking (IHI JU) Role : To translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research.
Executive Director: Dr Niklas Blomberg Partners : The EU (represented by the European Commission, COCIR (medical imaging, radiotherapy, health ICT and electromedical industries); EFPIA (biopharmaceutical industry), EuropaBio (biotechnology industry); MedTech Europe (medical technology industry) and Vaccines Europe (vaccine industry).
Location : Brussels (Belgium) Website : IHI Joint Undertaking Science is driving new developments that often span different sectors within the life science community. As a result, an increasing number of patients already use medical devices, digital technologies and e-health services alongside medicines as part of their healthcare.
Looking to the future, it’s clear that new breakthroughs will increasingly involve cross-sector discoveries , such as medical device-drug combinations or AI diagnostics. Yet all too often, the industrial sectors involved in health research and care (pharmaceutical, digital, IT, medical devices, diagnostics, etc.) work in isolation. We urgently need an innovative, more integrated approach to health research and healthcare .
turn health research and innovation into real benefits for patients and society deliver safe, effective health innovations that cover the entire spectrum of care – from prevention to diagnosis and treatment – particularly in areas where there’s an unmet public health need make Europe’s health industries globally competitive.
It funds collaborative, cross-sector research projects that bring together all the parties involved in health research, including: health-related industries small and medium-sized enterprises (SMEs) IHI builds on the successes and lessons learned through the Innovative Medicines Initiative , a partnership between the EU and the pharmaceutical industry.
IMI demonstrated that a public-private partnership approach delivers results in areas where there is a lack of safe, effective treatments (e.g. dementia ) and/or where the impact on public health is greatest (e.g. diabetes, antimicrobial resistance ). Patients can influence research into their conditions; in the longer term, they and society in general will benefit from faster access to better, safer medicines.
Academic researchers and SMEs gain knowledge and access to research funding. Larger companies gain knowledge and tools to improve their R&D activities. All project participants benefit from the expertise of other partners and the opportunity to translate scientific discoveries into useful tools and resources that will ultimately help improve healthcare.
Innovative Health Initiative Joint Undertaking (IHI JU) Name Innovative Health Initiative Joint Undertaking (IHI JU) Website https://www. ihi. europa.
eu/ Email infodesk ihi [dot] europa [dot] eu Phone number +32 2 221 81 81 Postal address IHI JU TO 56
Based on current listing details, eligibility includes: Nonprofit organizations, including NGOs, involved in health research and innovation within EU member states. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
AAI Career Awards is a grant from the American Association of Immunologists (AAI) that honors members for outstanding research and career achievement. Through multiple award tracks — including the Lifetime Achievement Award, Distinguished Service Award, Distinguished Fellows program, Public Service Award, and Vanguard Award — AAI recognizes immunologists at every career stage who have made exceptional scientific, institutional, or public-policy contributions. Nominations originate from the AAI Council and designated committees. The program celebrates careers defined by scientific excellence, service to the immunology community, and contributions to public advocacy, minority recruitment in the sciences, and disease research. Deadline is September 10, 2025.